Cargando…

Immunophenotypic aberrant hematopoietic stem cells in myelodysplastic syndromes: a biomarker for leukemic progression

Myelodysplastic syndromes (MDS) comprise hematological disorders that originate from the neoplastic transformation of hematopoietic stem cells (HSCs). However, discrimination between HSCs and their neoplastic counterparts in MDS-derived bone marrows (MDS-BMs) remains challenging. We hypothesized tha...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Spronsen, Margot F., Hanekamp, Diana, Westers, Theresia M., van Gils, Noortje, Vermue, Eline, Rutten, Arjo, Jansen, Joop H., Lissenberg-Witte, Birgit I., Smit, Linda, Schuurhuis, Gerrit J., van de Loosdrecht, Arjan A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991914/ https://www.ncbi.nlm.nih.gov/pubmed/36792658 http://dx.doi.org/10.1038/s41375-023-01811-5

Ejemplares similares

Computational flow cytometry as a diagnostic tool in suspected‐myelodysplastic syndromes
por: Duetz, Carolien, et al.
Publicado: (2021)

Challenging the status flow: how artificial intelligence is advancing diagnosis of myelodysplastic neoplasms
por: Duetz, Carolien, et al.
Publicado: (2023)

Distinct bone marrow immunophenotypic features define the splicing factor 3B subunit 1 (SF3B1)‐mutant myelodysplastic syndromes subtype
por: Duetz, Carolien, et al.
Publicado: (2021)

Dysregulation of developmental and cell type-specific expression of glycoconjugates on hematopoietic cells: a new characteristic of myelodysplastic neoplasms (MDS)
por: van Spronsen, Margot F., et al.
Publicado: (2023)

The Novel Oral BET-CBP/p300 Dual Inhibitor NEO2734 Is Highly Effective in Eradicating Acute Myeloid Leukemia Blasts and Stem/Progenitor Cells
por: van Gils, Noortje, et al.
Publicado: (2021)

Thrombomodulin-expressing monocytes are associated with low-risk features in myelodysplastic syndromes and dampen excessive immune activation
por: van Leeuwen-Kerkhoff, Nathalie, et al.
Publicado: (2020)

Escape From Treatment; the Different Faces of Leukemic Stem Cells and Therapy Resistance in Acute Myeloid Leukemia
por: van Gils, Noortje, et al.
Publicado: (2021)

Reduced frequencies and functional impairment of dendritic cell subsets and non-classical monocytes in myelodysplastic syndromes
por: van Leeuwen-Kerkhoff, Nathalie, et al.
Publicado: (2021)

Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation
por: van den Ancker, Willemijn, et al.
Publicado: (2010)

Durable Responses and Survival in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients Receiving the Allogeneic Leukemia-derived Dendritic Cell Vaccine DCP-001
por: Janssen, Luca L.G., et al.
Publicado: (2023)

A series of case studies illustrating the role of flow cytometry in the diagnostic work‐up of myelodysplastic syndromes
por: Westers, Theresia M., et al.
Publicado: (2022)

Divergent Autologous T Cell Responses to Leukaemic Dendritic Cells during Remission in Acute Promyelocytic Leukaemia
por: Westers, Theresia M., et al.
Publicado: (2005)

Specific Depletion of Leukemic Stem Cells: Can MicroRNAs Make the Difference?
por: Martiáñez Canales, Tania, et al.
Publicado: (2017)

Targeting histone methylation to reprogram the transcriptional state that drives survival of drug-tolerant myeloid leukemia persisters
por: van Gils, Noortje, et al.
Publicado: (2022)

Leukemic Stem Cell Frequency: A Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia
por: Terwijn, Monique, et al.
Publicado: (2014)

Management of patients with lower-risk myelodysplastic syndromes
por: Brunner, Andrew M., et al.
Publicado: (2022)

EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up for Myelodysplastic Syndromes
por: van de Loosdrecht, Arjan A., et al.
Publicado: (2022)

Immunophenotypic changes of monocytes in myelodysplastic syndrome and clinical significance
por: Li, Lijuan, et al.
Publicado: (2022)

Human Bone Marrow-Derived Myeloid Dendritic Cells Show an Immature Transcriptional and Functional Profile Compared to Their Peripheral Blood Counterparts and Separate from Slan+ Non-Classical Monocytes
por: van Leeuwen-Kerkhoff, Nathalie, et al.
Publicado: (2018)

Differential capacity of human interleukin-4 and interferon-α monocyte-derived dendritic cells for cross-presentation of free versus cell-associated antigen
por: Ruben, Jurjen M., et al.
Publicado: (2015)

Prognostic impact of immunophenotypic aberrancies of blasts in lower risk myelodysplastic syndrome
por: Corrao, Kristen, et al.
Publicado: (2022)

Management of infection prophylaxis in Dutch patients with myelodysplastic syndromes, a web‐based case vignette questionnaire: The MINDSET study
por: Rozema, Johanne, et al.
Publicado: (2022)

Myeloblasts transition to megakaryoblastic immunophenotypes over time in some patients with myelodysplastic syndromes
por: Ogata, Kiyoyuki, et al.
Publicado: (2023)

Increased prescription rate of anti‐infective agents after diagnosis of myelodysplastic syndromes
por: Rozema, Johanne, et al.
Publicado: (2022)

Predicting leukemic transformation in myelodysplastic syndrome using a transcriptomic signature
por: Guo, Chao, et al.
Publicado: (2023)

Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia
por: Zeijlemaker, Wendelien, et al.
Publicado: (2019)

Clonal evolution in myelodysplastic syndromes
por: da Silva-Coelho, Pedro, et al.
Publicado: (2017)

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions
por: Valent, Peter, et al.
Publicado: (2017)

Abnormal platelet immunophenotypes and percentage of giant platelets in myelodysplastic syndrome: A pilot study
por: Wu, Yi-Feng, et al.
Publicado: (2022)

Isolation, culture, and immunophenotypic analysis of bone marrow HSPCs from patients with myelodysplastic syndromes
por: Ganan-Gomez, Irene, et al.
Publicado: (2022)

Promiscuous Binding of Invariant Chain-Derived CLIP Peptide to Distinct HLA-I Molecules Revealed in Leukemic Cells
por: van Luijn, Marvin M., et al.
Publicado: (2012)

P475: EMERGING LEUKEMIA ASSOCIATED IMMUNOPHENOTYPES (LAIPS) IN BONE MARROW OF ACUTE MYELOID LEUKEMIA PATIENTS AFTER INTENSIVE CHEMOTHERAPY.
por: Lam Ngai, Lok, et al.
Publicado: (2023)

FBXO11 is a candidate tumor suppressor in the leukemic transformation of myelodysplastic syndrome
por: Schieber, Michael, et al.
Publicado: (2020)

Immunophenotyping in Myelodysplastic Syndromes Can Add Prognostic Information to Well-Established and New Clinical Scores
por: Reis-Alves, Suiellen C., et al.
Publicado: (2013)

A Human Cell Line Model for Interferon-α Driven Dendritic Cell Differentiation
por: Ruben, Jurjen M., et al.
Publicado: (2015)

Indispensable role of immunophenotyping in diagnosing leukemic phase of blastic plasmacytoid dendritic cell neoplasm without cutaneous manifestation
por: Alam, Hareem, et al.
Publicado: (2022)

Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes
por: van Luijn, Marvin M., et al.
Publicado: (2010)

A simple score derived from bone marrow immunophenotyping is important for prognostic evaluation in myelodysplastic syndromes
por: Vido-Marques, J. R., et al.
Publicado: (2020)

PB2027: EFFICACY OF THERAPY IN PATIENTS WITH NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROME WITH UNFAVORABLE IMMUNOPHENOTYPIC AND CYTOGENETIC PROGNOSIS.
por: Trubkina, Hanna, et al.
Publicado: (2023)

Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group
por: Porwit, Anna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gv3dj16ickc2s2uad5esqo6776